Corporate Background

Alpha Cancer Technologies Inc., (ACT) is a private clinical stage biotechnology company with products under development in auto-immune and oncology disease indications. The company's drug products use proprietary recombinant human alpha fetoprotein (AFP) technology with unique immuno-oncology properties.

In Immunology the company is ready to enter Phase II clinical trials in Myasthenia Gravis (MG) (for which the Company received Orphan Drug Designation from the FDA) followed by Phase II clinical trials in Inflammatory Bowel Disease (IBD) and Multiple Sclerosis (MS). ACT-101 (AFP) has been shown to be as safe as placebo in clinical trials in over 300 patients. **In Oncology** AFP can deliver chemotherapy on a targeted basis to provide greater efficacy with significantly reduced toxicity.

Celgene, one of the world's largest biotechnology companies (~US$90 Billion market capitalization) owns a 12% equity stake in ACT.

The company has a significantly mitigated risk profile in every area of development and an expedited clinical development path.

Compelling Rationale – Game Changer

In Immunology it is well-known that autoimmune diseases in women typically go into remission during pregnancy and there is a strong correlation between the level of AFP in mother's blood and the decrease in the symptoms of her disease. In preclinical models of MG, AFP was able to block the binding of MG antibodies to the receptors. In addition, pre-clinical studies demonstrated efficacy of rHuAFP in animal models of IBD and MS.

In Oncology AFP is a carrier protein known for transporting nutrients to rapidly growing fetal cells and also acts as an immune regulatory protein involved in the protection of the fetus from attack by the mother's immune system. Only trace amounts of the protein are found following the fetal stage but receptors for AFP show up again on almost all solid and liquid cancer cells. The company uses its proprietary AFP to deliver a chemotherapy payload to selectively kill cancer cells. Lower toxicity of this targeted approach offers the ability to treat the patient more frequently until the patient is cancer free.

Product Pipeline

ACT has several lead products that include non-covalently bound chemotherapy (paclitaxel, thapsigargin) and chemically linked chemotherapy such as maytansine. In addition to proven efficacy and known safety profile of generic chemotherapy drugs, AFP itself has been proven as safe as placebo in over 300 patients in Phase I and II clinical studies. ACT's products are being developed as a treatment for multiple cancer indications as almost all cancer cells (>80%) express AFP receptors and healthy cells do not.

Therapy	Indication	Partners	Discovery	Pre-clinical	Phase I	Phase II
ACT-101 (AFP)	**Autoimmune** a) Myasthenia Gravis (muscle weakness) b) Inflammatory Bowel Disease (Crohn's/Colitis) c) Multiple Sclerosis d) Hashimoto Disease e) Other Autoimmune					
ACT-901 (AFP + paclitaxel)	**Targeted Oncology** Solid and liquid tumors	Collaboration University Health Network				
ACT-902 AFP + thapsigargin	**Targeted Oncology** Solid and liquid tumors	Collaboration University Health Network, Princess Margaret Cancer Center				

ACT-903 AFP + Linker + maytansine	**Targeted Oncology** Solid and liquid tumors	Collaboration Polytherics (Abzena) U.K.	

Preclinical Studies

In collaboration with researchers at the University Health Network and the Ontario Cancer Institute/Princess Margaret Cancer Centre in Toronto, ACT has completed preclinical studies examining the activity, safety and efficacy of ACT-901 and ACT-902. In vitro and in vivo results have shown that ACT-901 (AFP+ paclitaxel) and ACT-902 (AFP+thapsigargin) can successfully target and kill cancer cells with little to no toxicity and without the "off-target" damage to healthy cells. ACT-903 (AFP+linker+maytansine) is ongoing similar studies currently.

A targeted delivery platform technology, transporting a well-established chemotherapeutic drug directly to cancer cells, will enable uptake and use of ACT's platform in multiple forms of cancer; starting with ovarian and testicular germ cell cancer, rare disease indications, providing ACT-901 a valuable orphan drug designation in the US and Europe, and early commercial approval and expanding usage to other solid and liquid based cancers. Dr. Daniel Von Hoff, a key opinion leader, is advising the company on the upcoming clinical trials.

Additional Potential Benefits of ACT's Approach

Immuno-oncology is currently one of the most active areas of research with almost every major pharmaceutical company developing such products. However, almost all of the approaches being explored aim at unblocking a specific immune check-point in the very complex universe of immune system interactions and carry risk of serious side-effects. Recent data suggest that myeloid-derived suppressor cells (MDSCs) may play a major role in allowing tumors to escape immune surveillance. MDSCs are present in large numbers in the vicinity of most cancers and when activated suppress the activity of T cells and NK cells. Our recent work shows evidence that MDSCs express AFP receptors. We therefore expect that ACT's targeted therapies will not only kill cancer cell by selectively delivering chemotherapy drugs to these cells but also have the potential to release the patient's immune system to attack cancers by killing immuno-suppressive MDSCs thus combining immuno- and chemotherapy actions and delivering a double knockout hit to most cancers.

Management

Mr. Potts is the Chairman of ACT, bringing a proven track record of management, finance and marketing of growth companies across a diverse spectrum of industries, including biotechnology, medical and information technology. Two earlier life science companies founded by Mr. Potts attained market capitalization values of $250 million and $1.5 billion.

Dr. Sherman brings extensive experience and expertise in the pharmaceutical and biotechnology industry, particularly in oncology. Prior to ACT, Dr. Sherman was Director of Clinical Research and Director of Scientific Affairs for YM Biosciences Inc., where he was responsible for preclinical and clinical development, as well as registration strategies for all oncology and pain products in YM Biosciences' portfolio. Dr. Sherman was also Scientific Director of Oncology for AstraZeneca Canada Inc.

ACT's delivery technology targets receptors on cancer cells. Watch an animation at www.alpha-cancer.com